This subgroup of patients showed an improved PFS (HR 0.76) with durvalumab, although only 43 EGFR mutant NSCLC patients were enrolled in the PACIFIC study, and the confidence interval crossed 1 [37]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.